A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03-Reference-Cited by-同舟云学术

A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03

Published:2015-11 Issue:45 Volume:33 Page:6078-6084
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Naruse Takeshi,Fukuda Tadashi,Tanabe Tetsuro,Ichikawa Munetaka,Oda Yoshiaki,Tochihara Shinji,Kimachi Kazuhiko,Kino Yoichiro,Ueda Kohji

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference23 articles.

1. WHO global influenza preparedness plan: The role of WHO and recommendations for national measures before and during pandemics;World Health Organization,2005

2. Chapter 4 Ensuring healthful and safe living: Part 2 Responses to current political challenges;Ministry of Health. Labor and Welfare,2012

3. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine;Leroux-Roels;PLoS ONE,2008

4. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial;Leroux-Roels;Lancet,2007

5. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults;Langley;J Infect Dis,2010

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innovations in cell culture-based influenza vaccine manufacturing – from static cultures to high cell density cultivations;Human Vaccines & Immunotherapeutics;2024-07-15

2. Cross-Reactivity Conferred by Homologous and Heterologous Prime-Boost A/H5 Influenza Vaccination Strategies in Humans: A Literature Review;Vaccines;2021-12-10

3. Immunogenicity and protective efficacy of an EB66® cell culture-derived duck Tembusu virus vaccine;Avian Pathology;2020-07-02

4. Clinical phase II and III studies of an AS03‐adjuvanted H5N1 influenza vaccine produced in an EB66 ® cell culture platform;Influenza and Other Respiratory Viruses;2020-06-24

5. The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial;Journal of Microbiology, Immunology and Infection;2019-10